Anavex Announces Panel Discussion and Presentation at OneMedForum Conference

NEW YORK, NY – January 8, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL), a clinical stage biopharmaceutical company currently in a Phase 2a clinical trial for Alzheimer’s disease, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will participate in a panel discussion entitled “Neurology and Brain…

Anavex Encouraged by Scientific Data Confirming Sigma-1 Receptor’s Beneficial Direct Interaction with Cannabinoid Receptor

Report Expands Opportunity for Therapeutic Application of Proprietary Anavex Compounds in Neurological Diseases New York — January 6, 2015 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) welcomes new data published in the current issue of the International Journal of Neuropsychopharmacology (IJNP) revealing that the sigma-1 receptor, the Company’s drug target, interacts positively and directly…